• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 27, 2011

View Archived Issues

Killing Bacteria is Not the Only Way to Fight Them

Any infection is a battle between the body and the immune system. Killing as many bacterial foot soldiers as possible is one way to help the body win this battle. But another possibility is to strip bacteria of their weapons in the fight without killing them outright – an approach termed non-bactericidal. Read More

Grappling with Drug-Induced Liver Toxicity - Bane of Biotech

Despite biopharmas' best efforts, around 40 percent of cases of drug-induced liver injury aren't discovered in preclinical studies. That stands in stark contrast to toxicity in hematological, gastrointestinal and cardiovascular systems, where only 10 percent to 20 percent of problems aren't caught in preclinical studies. Read More

Trius Data Show Antibiotic Guidelines Feasible, for Now

Over the past five years, regulatory chaos in the antibiotics field has created a sort of solidarity between biotechs that would otherwise be competitors. Read More

Week in Review

Financings Excelimmune Inc. raised $12 million from a private investor to support its infectious disease work. Medicago Inc. closed the second tranche of a $21.8 million private placement. Perosphere Inc. raised $1 million privately in initial funding for its drug delivery programs. Radius Health Inc. closed the final tranche of its previously announced $91 million financing. Read More

Word on the Street

"There will be a time when I recommend someone bringing an obesity product, but it's not going to be this decade."– Joshua Boger, retired founder and CEO of Vertex Pharmaceuticals Inc., talking about the increasing strictness of the FDA when it comes to risk-benefit analysis of drugs under review"If you do a deal with somebody and it doesn't go well, you always want to be nice because it's a really, really small world."– John Fisher, founder of Biopsy Sciences Inc. Read More

Week in Washington

The House passed H.R. 2055, the 2012 omnibus spending bill, which included $576.5 million for the creation of the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH).The NIH is halting funding for new drug research involving chimpanzees after an Institute of Medicine report found "most current use of chimpanzees for biomedical research is unnecessary" in light of new technologies. Read More

Biotechnology Company Deals With Other Biotechnology Companies: November 1 - December 22, 2011

Total Value in 2011: $8,451.1M*Number of Deals in 2011: 200Company (Location)Company (Location)Value (M)Type/Product AreaTerms/Details (Date)NOVEMBERAccess Pharmaceuticals Inc. (Dallas) Read More

Top 10 Deals Between Biotech Companies: 2011

CompanyCompanyDeal ValueVertex Pharmaceuticals Inc.Alios Biopharma Inc.$1.5B (June)Amgen Inc.Micromet Inc.$976M (July)Genentech Inc.Array BioPharma Inc.$713M (August)Biogen Idec Inc.Portola Pharmaceuticals Inc.$554M (October) Read More

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: Nov. 1 - Dec. 22, 2011

Company (Location)Company (Location)Value (M)Type/Product AreaTerms/Details (Date)NOVEMBERAmgen Inc. (Thousand Oaks, Calif.)DaVita Inc. (Torrence, Calif.)ND Read More

Biotech–Biotech Collaborations: Modified Agreements: November 1 - December 22, 2011

Company (Location)Company (Location)Value (M)Type/Product AreaTerms/Details (Date)I. Modified AgreementsNOVEMBERExonHit SA (Paris)Allergan Inc. (Irvine, Calif.)ND Read More

Money Raised By Biotech In 2011 Vs. 2010

Read More

Money Raised By Biotech: Jan. 1 - Dec. 22, 2011

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe